Literature DB >> 11161825

Characterization of the mouse phenylalanine hydroxylase mutation Pah(enu3).

M J Haefele1, G White, J D McDonald.   

Abstract

Phenylketonuria (PKU) is an inborn error of metabolism that is inherited in an autosomal recessive manner. It arises from a deficiency of phenylalanine hydroxylase, which is responsible for converting phenylalanine to tyrosine and thereby hastening its catabolism. To produce mouse models for the study of PKU, male mice were mutagenized with ethylnitrosourea and their progeny were screened for the elevated phenylalanine levels characteristic of phenylalanine hydroxylase deficiency. Of three mutant alleles recovered, two (Pah(enu1) and Pah(enu2)) were characterized previously and shown to be missense mutations. Sequencing of phenylalanine hydroxylase cDNA from the third mutant allele, Pah(enu3), revealed that two differently sized transcripts were being produced. These transcripts contained either a 5-nucleotide insertion or a 5-nucleotide deletion and both of these modifications occurred at the same location, the exon 11-exon 12 junction. Sequencing of the exon 11-intron 11 boundary revealed a T --> G transversion in the invariant GT dinucleotide of the wild-type 5' splice donor site. The analogous human Pah mutation would be called c.1199 + 2T > G. Sequence analysis also revealed two cryptic splice donor sites, upstream and downstream of the wild-type splice site, that appear to be used when the wild type is ablated and to thereby yield the observed differently sized transcripts. The 5-nucleotide insertion and the 5-nucleotide deletion are both predicted to cause frame shifting in exon 12 and exon 13, leading to premature termination. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161825     DOI: 10.1006/mgme.2000.3104

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  5 in total

1.  In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria.

Authors:  Gladys Ho; Juergen Reichardt; John Christodoulou
Journal:  J Inherit Metab Dis       Date:  2013-03-27       Impact factor: 4.982

2.  Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.

Authors:  Angel L Pey; Ming Ying; Nunilo Cremades; Adrian Velazquez-Campoy; Tanja Scherer; Beat Thöny; Javier Sancho; Aurora Martinez
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

3.  A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency.

Authors:  Daelyn Y Richards; Shelley R Winn; Sandra Dudley; Lev Fedorov; Nicole Rimann; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2020-09-30       Impact factor: 4.797

Review 4.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

5.  The Pah-R261Q mouse reveals oxidative stress associated with amyloid-like hepatic aggregation of mutant phenylalanine hydroxylase.

Authors:  Oscar Aubi; Karina S Prestegård; Kunwar Jung-Kc; Tie-Jun Sten Shi; Ming Ying; Ann Kari Grindheim; Tanja Scherer; Arve Ulvik; Adrian McCann; Endy Spriet; Beat Thöny; Aurora Martinez
Journal:  Nat Commun       Date:  2021-04-06       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.